Patents by Inventor Franz Weiberth

Franz Weiberth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070142351
    Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.
    Type: Application
    Filed: December 21, 2006
    Publication date: June 21, 2007
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: James Hendrix, Joseph Strupczewski, Kenneth Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerte, John Jurcak, Harpal Gill, Franz Weiberth, Thaddeus Nieduzak, Sharon Jackson, Xu-Yang Zhao, Paul Mueller
  • Patent number: 7112682
    Abstract: An improved process for the preparation of N-amino nitrogen heterocyclic compounds is disclosed and claimed. In an embodiment of this invention, a compound of the formula (VI) is prepared starting from the corresponding indole derivative by way of N-amination and subsequently forming an hydrazone by the reaction with a keto compound in a single step. Further reduction of the hydrazone and subsequent coupling with a pyridine compound affords the compound of formula VI or a suitable salt thereof.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: September 26, 2006
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Franz Weiberth, George Everett Lee, Reda G. Hanna, Juergen Mueller-Lehar, Silke Dubberke, Roland Utz
  • Publication number: 20050107389
    Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.
    Type: Application
    Filed: October 7, 2004
    Publication date: May 19, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: James Hendrix, Joseph Strupczeski, Kenneth Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerle, John Jurcak, Harpal Gill, Franz Weiberth, Thaddeus Nieduzak, Sharon Jackson, Xu-Yang Zhao, Paul Mueller
  • Publication number: 20050101654
    Abstract: An improved process for the preparation of N-amino nitrogen heterocyclic compounds is disclosed and claimed. In an embodiment of this invention, a compound of the formula (VI) is prepared starting from the corresponding indole derivative by way of N-amination and subsequently forming an hydrazone by the reaction with a keto compound in a single step. Further reduction of the hydrazone and subsequent coupling with a pyridine compound affords the compound of formula VI or a suitable salt thereof.
    Type: Application
    Filed: October 1, 2004
    Publication date: May 12, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Franz Weiberth, George Lee, Reda Hanna, Juergen Mueller-Lehar, Silke Dubberke, Roland Utz